IntelGenx Obtains Preliminary Efficacy Results for the 'BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Stock Information for IntelGenx Technologies Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IntelGenx Technologies Corp.

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.